These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 17981670)

  • 41. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation.
    Zingarelli B; Cook JA
    Shock; 2005 May; 23(5):393-9. PubMed ID: 15834303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD200R1 and CD200 expression are regulated by PPAR-γ in activated glial cells.
    Dentesano G; Serratosa J; Tusell JM; Ramón P; Valente T; Saura J; Solà C
    Glia; 2014 Jun; 62(6):982-98. PubMed ID: 24639050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
    Feinstein DL; Spagnolo A; Akar C; Weinberg G; Murphy P; Gavrilyuk V; Dello Russo C
    Biochem Pharmacol; 2005 Jul; 70(2):177-88. PubMed ID: 15925327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
    Ahsan W
    Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 47. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms.
    Ray DM; Akbiyik F; Phipps RP
    J Immunol; 2006 Oct; 177(8):5068-76. PubMed ID: 17015690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
    Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.
    Collino M; Aragno M; Mastrocola R; Gallicchio M; Rosa AC; Dianzani C; Danni O; Thiemermann C; Fantozzi R
    Eur J Pharmacol; 2006 Jan; 530(1-2):70-80. PubMed ID: 16386242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis.
    Choo J; Lee Y; Yan XJ; Noh TH; Kim SJ; Son S; Pothoulakis C; Moon HR; Jung JH; Im E
    J Biol Chem; 2015 Oct; 290(42):25609-19. PubMed ID: 26342083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanomolar and micromolar effects of 15-deoxy-delta 12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B.
    Berry EB; Keelan JA; Helliwell RJ; Gilmour RS; Mitchell MD
    Mol Pharmacol; 2005 Jul; 68(1):169-78. PubMed ID: 15821150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PPAR agonists for the treatment of neuroinflammatory diseases.
    Titus C; Hoque MT; Bendayan R
    Trends Pharmacol Sci; 2024 Jan; 45(1):9-23. PubMed ID: 38065777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG; Hele DJ; Birrell MA
    Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
    Vázquez M; Silvestre JS; Prous JR
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
    Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
    Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) protects neurons from oxidative death via an Nrf2 astrocyte-specific mechanism independent of PPARγ.
    Haskew-Layton RE; Payappilly JB; Xu H; Bennett SA; Ratan RR
    J Neurochem; 2013 Feb; 124(4):536-47. PubMed ID: 23199167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.
    Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Maffia P; Patel NS; Di Paola R; Ialenti A; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
    Eur J Pharmacol; 2004 Jan; 483(1):79-93. PubMed ID: 14709329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.
    Coyle AT; Kinsella BT
    Biochem Pharmacol; 2006 Apr; 71(9):1308-23. PubMed ID: 16499875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.